The results show that FOXM1-PROTAC had a more potent inhibitory effect on cancer cell viability than peptide FIP-1 (Fig. 3B), which is expected as FIP-1 inhibits FOXM1 only by binding to FOXM1, whereas FOXM1-PROTAC eliminates the majority of FOXM1 and can bind to the remaining nondegraded FOXM1. The gene discussed is FOXM1; the disease is cancer.